Cargando…

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)

Detalles Bibliográficos
Autores principales:	Wittkowski, H, Kuemmerle-Deschner, JB, Gramlich, K, Tzaribachev, N, Felix, SD, Jung, T, Roth, J, Rordorf, C, Foell, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334013/ http://dx.doi.org/10.1186/1546-0096-6-S1-P209

Ejemplares similares

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Delayed diagnosis of Muckle-Wells syndrome – analysis of influencing factors
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2012)

IL-1 inhibition in Muckle-Wells-Syndrome: withdrawal resulting in rapid deterioration of hearing loss
por: Hansmann, S, et al.
Publicado: (2015)

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2013)

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2008)

Early detection of sensorineural hearing loss in Muckle-Wells-syndrome
por: Kuemmerle-Deschner, Jasmin B., et al.
Publicado: (2015)

NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

PW02-042 - Induction of MDSC in Muckle-Wells syndrome
por: Rieber, N, et al.
Publicado: (2013)

PReS-FINAL-2336: Induction of MDSCS in Muckle-Wells syndrome
por: Rieber, N, et al.
Publicado: (2013)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Human S100A8 and S100A9 activate phagocytes via Toll-like receptor 4 independent of RAGE
por: Vogl, T, et al.
Publicado: (2009)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series
por: Tzaribachev, Nikolay, et al.
Publicado: (2009)

Muckle–Wells syndrome: clinical perspectives
por: Tran, Tu-Anh
Publicado: (2017)

Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis
por: Tzaribachev, N, et al.
Publicado: (2008)

Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature
por: Marchica, Cinzia, et al.
Publicado: (2018)

Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network
por: Gaggiano, Carla, et al.
Publicado: (2021)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

A large family having Muckle Wells Syndrome
por: Kilic, SS, et al.
Publicado: (2015)

Somatic NLRP3 mosaicism in Muckle-Wells syndrome
por: Gonzalez-Roca, E, et al.
Publicado: (2015)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Successful autologous stem cell transplantation (ASCT) in a patient with juvenile dermatomyositis
por: Holzer, U, et al.
Publicado: (2008)

P02-028 - Muckle-Wells syndrome and renal transplantation
por: Kortus-Götze, B, et al.
Publicado: (2013)

O056 The effect of acetazolamide and oxygen (ACZ+O2) combination therapy on loop gain and OSA severity
por: Landry, S, et al.
Publicado: (2022)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Hypofertility in Muckle Wells syndrome and treatment with IL-1 targeting drugs
por: Meinzer, Ulrich, et al.
Publicado: (2011)

Muckle–Wells syndrome in an Indian family associated with NLRP3 mutation
por: Abdulla, MC, et al.
Publicado: (2015)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

The Damage Associated Molecular Pattern (DAMP) molecule S100A12 induces pro-inflammatory responses in monocytes via innate immunity signalling pathways
por: Wittkowski, H, et al.
Publicado: (2008)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Erratum: Muckle–Wells syndrome in an Indian family associated with NLRP3 mutation
Publicado: (2020)

Familial case of Muckle-Wells syndrome in the Russian population: a long way to the diagnosis
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sa2jkhrjdl59i9ftfojr7kcme9